Trading Signals: TNXP Stock Price Prediction and Forecast (Fri. Feb. 3, 2012 - Fri. May. 13, 2022)(Tonix Pharmaceuticals)
| TNXP latest price $7210.0000 (8.26%) ($6618.0000 - $7345.0000) on Mon. Aug. 31, 2015. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.18% (three month average) | RSI | 43 | Latest Price | $7210.0000(8.26%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TNXP advances 3.2% a day on average for past five trading days. | Weekly Trend | TNXP declines -4.4% a week on average for past two weeks. | Market Behavior | Value stocks sell-off for large cap. Value stock sell-off for small cap. | Correlated ETFs | Broad market will support TNXP advance at 0% a week (0% probability) XBI(18%) IBB(17%) IWO(16%) ARKG(15%) IWM(15%) | Factors Impacting TNXP price | TNXP will decline at least -2.09% in a week (0% probabilities). VIXM(-7%) TLT(-5%) GLD(-5%) BWX(-5%) SHY(-4%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.09% (StdDev 4.18%) | Hourly BBV | 0 () | Intraday Trend | 8.1% | | | |
|
1 - 5 Day Possible Target | $6750.49(-6.37%) | 5 Day Moving Average | $6560(9.91%) | 10 Day Moving Average | $6641.25(8.56%) | 20 Day Moving Average | $7042.38(2.38%) | To recent high | -31.3% | To recent low | 17.8% | Market Cap | $1910.65b | | | | Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecules and biologics to treat psychiatric, pain and addiction conditions, to improve biodefense through potential medical counter-measures, to treat transplant rejection and to treat gastric and pancreatic cancers. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and Tonmya. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in New York, NY.July 16, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it has entered into a research collaboration and option agreement with Columbia University focused on studying the immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic. The research collaboration will focus on T cell and antibody responses to SARS-CoV-2 (CoV-2), the virus that causes COVID-19 at the cellular level including human monoclonal antibodies and anti-idiotypes. The research is designed to fill in important gaps in understanding the detailed immune responses to COVID-19, and to provide a foundation upon which to target vaccines and therapeutics to appropriate individuals by precision medicine. |